ABVX

Abivax
ABVX
Market cap $434M

6.84 USD

-0.09

1.30%

At close Apr 25, 4:00 PM EDT

1 day

-1.30%

5 days

4.11%

1 month

-6.81%

3 months

12.13%

6 months

-33.59%

Year to date

-6.17%

1 year

-56.54%

5 years

-17.59%

10 years

-17.59%

About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Employees: 69

Healthcare Biotechnology

0

Funds holding %

of 7,419 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

20% more funds holding

Funds holding: 40 [Q3] → 48 (+8) [Q4]

3.88% more ownership

Funds ownership: 43.26% [Q3] → 47.14% (+3.88%) [Q4]

30% less capital invested

Capital invested by funds: $313M [Q3] → $219M (-$94.3M) [Q4]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

75%

upside

Avg. target

$23

229%

upside

High target

$33

382%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Morgan Stanley Judah Frommer 40% 1-year accuracy 4 / 10 met price target	75%upside $12	Equal-Weight Assumed	20 Mar 2025
Citizens Capital Markets Jason Butler 28% 1-year accuracy 11 / 40 met price target	382%upside $33	Market Outperform Reiterated	18 Mar 2025

See Analyst Rankings

Financial journalist opinion

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, France Phase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that the upcoming Annual General Meeting will be held on June 6, 2025, in Paris, France. Additional information and preparatory documents for this Annual General Meeting will be made available in the coming weeks in accordance with applicable legal and regulatory requirements.

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in global biopharma, most notably a 20-year tenure at AbbVie/Abbott, where he served as Vice President of Global Marketing for Immunology and later as Head of Global Medical Affairs.

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025. The Universal Registration Document includes the 2024 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax Announces Full Year 2024 Financial Results

Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France – March 24, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of December 31, 2024. The 2024 financial statements, approved by the Company's Board of Directors on March 20, 2025, have been audited by the Company's statutory auditors, and the financial reports will be filed with the French and U.S. securities regulatory authorities, respectively, on March 24, 2025.

Abivax Announces Full Year 2024 Financial Results

Zacks Investment Research

Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High?

The consensus price target hints at a 360.5% upside potential for Abivax SA Sponsored ADR (ABVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High?

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax's Pivotal ABTECT Phase 3 Trial PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m.

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Zacks Investment Research

Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet

The mean of analysts' price targets for Abivax SA Sponsored ADR (ABVX) points to a 427.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet

Zacks Investment Research

Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks

Abivax SA Sponsored ADR (ABVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks

Abivax Publishes 2025 Financial Calendar

Abivax Publishes 2025 Financial Calendar PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communications calendar. Monday, March 24, 2025 (after US Market closes) 2024 Annual Business and Financial Report (as of December 31, 2024) Press Release Universal Registration Document (Euronext) Annual Report on Form 20-F Monday, June 2, 2025 (after US Market closes) 2025 Q1 Financial Results (as of March 31, 2025) Press Release Report on Form 6-K Friday, June 6, 2025 2025 Annual General Meeting (AGM) Live meeting in Paris, France Monday, August 11, 2025 (after US Market closes) 2025 Half-Year Business and Financial Report (as of June 30, 2025) Press Release Half-Year Financial Report (Euronext) Report on Form 6-K Monday, December 15, 2025 (after US Market closes) 2025 Q3 Financial Results (as of September 30, 2025) Press Release Report on Form 6-K About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

See News Rankings

Charts implemented using Lightweight Charts™